AAA- a further step towards a moratorium for aspirin in the primary prevention
Gespeichert in:
| Veröffentlicht in: | VASA 2010-05, Vol.39 (2), p.119-122 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 122 |
|---|---|
| container_issue | 2 |
| container_start_page | 119 |
| container_title | VASA |
| container_volume | 39 |
| creator | Minar, E |
| description | |
| doi_str_mv | 10.1024/0301-1526/a000016 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733150135</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733150135</sourcerecordid><originalsourceid>FETCH-LOGICAL-c252t-903edf8ddb83c5480d57303273b57ba6d59bf0284616ac070bada18e09013e153</originalsourceid><addsrcrecordid>eNo9kE9LxDAQxYMo7rr6AbxIbp7qziRN2j2WxX-w6EXPIW1SrGybmrSK396UrTsMDMy89xh-hFwj3CGwdA0cMEHB5FpDLJQnZIlSpgnLM3ZKlsf7glyE8AnAMMf0nCwYCIYpT5fkpSiKhGpaj374sJ6GwfZ0cD_amxDXrfN6cL4ZW1o7T3XoG990NHZU0943rfa_cdpv2w2N6y7JWa33wV7Nc0XeH-7ftk_J7vXxeVvskooJNiQb4NbUuTFlziuR5mBExoGzjJciK7U0YlPWwPJUotQVZFBqozG3sAHkFgVfkdtDbu_d12jDoNomVHa_1511Y1AZ5yiidlLiQVl5F4K3tZq_VghqoqgmSmqipGaK0XMzp49la83R8Y-N_wGaYWvK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733150135</pqid></control><display><type>article</type><title>AAA- a further step towards a moratorium for aspirin in the primary prevention</title><source>MEDLINE</source><source>Hogrefe eContent</source><creator>Minar, E</creator><creatorcontrib>Minar, E</creatorcontrib><identifier>ISSN: 0301-1526</identifier><identifier>EISSN: 1664-2872</identifier><identifier>DOI: 10.1024/0301-1526/a000016</identifier><identifier>PMID: 20521434</identifier><language>eng</language><publisher>Switzerland</publisher><subject>Aged ; Ankle Brachial Index ; Aspirin - adverse effects ; Aspirin - therapeutic use ; Atherosclerosis - complications ; Atherosclerosis - diagnosis ; Atherosclerosis - drug therapy ; Atherosclerosis - mortality ; Cardiovascular Agents - adverse effects ; Cardiovascular Agents - therapeutic use ; Cardiovascular Diseases - etiology ; Cardiovascular Diseases - mortality ; Cardiovascular Diseases - prevention & control ; Evidence-Based Medicine ; Female ; Hemorrhage - chemically induced ; Humans ; Male ; Middle Aged ; Primary Prevention - methods ; Randomized Controlled Trials as Topic ; Research Design ; Risk Assessment ; Scotland - epidemiology ; Time Factors ; Treatment Outcome</subject><ispartof>VASA, 2010-05, Vol.39 (2), p.119-122</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20521434$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Minar, E</creatorcontrib><title>AAA- a further step towards a moratorium for aspirin in the primary prevention</title><title>VASA</title><addtitle>Vasa</addtitle><subject>Aged</subject><subject>Ankle Brachial Index</subject><subject>Aspirin - adverse effects</subject><subject>Aspirin - therapeutic use</subject><subject>Atherosclerosis - complications</subject><subject>Atherosclerosis - diagnosis</subject><subject>Atherosclerosis - drug therapy</subject><subject>Atherosclerosis - mortality</subject><subject>Cardiovascular Agents - adverse effects</subject><subject>Cardiovascular Agents - therapeutic use</subject><subject>Cardiovascular Diseases - etiology</subject><subject>Cardiovascular Diseases - mortality</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Evidence-Based Medicine</subject><subject>Female</subject><subject>Hemorrhage - chemically induced</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Primary Prevention - methods</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Research Design</subject><subject>Risk Assessment</subject><subject>Scotland - epidemiology</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0301-1526</issn><issn>1664-2872</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE9LxDAQxYMo7rr6AbxIbp7qziRN2j2WxX-w6EXPIW1SrGybmrSK396UrTsMDMy89xh-hFwj3CGwdA0cMEHB5FpDLJQnZIlSpgnLM3ZKlsf7glyE8AnAMMf0nCwYCIYpT5fkpSiKhGpaj374sJ6GwfZ0cD_amxDXrfN6cL4ZW1o7T3XoG990NHZU0943rfa_cdpv2w2N6y7JWa33wV7Nc0XeH-7ftk_J7vXxeVvskooJNiQb4NbUuTFlziuR5mBExoGzjJciK7U0YlPWwPJUotQVZFBqozG3sAHkFgVfkdtDbu_d12jDoNomVHa_1511Y1AZ5yiidlLiQVl5F4K3tZq_VghqoqgmSmqipGaK0XMzp49la83R8Y-N_wGaYWvK</recordid><startdate>201005</startdate><enddate>201005</enddate><creator>Minar, E</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201005</creationdate><title>AAA- a further step towards a moratorium for aspirin in the primary prevention</title><author>Minar, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c252t-903edf8ddb83c5480d57303273b57ba6d59bf0284616ac070bada18e09013e153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Ankle Brachial Index</topic><topic>Aspirin - adverse effects</topic><topic>Aspirin - therapeutic use</topic><topic>Atherosclerosis - complications</topic><topic>Atherosclerosis - diagnosis</topic><topic>Atherosclerosis - drug therapy</topic><topic>Atherosclerosis - mortality</topic><topic>Cardiovascular Agents - adverse effects</topic><topic>Cardiovascular Agents - therapeutic use</topic><topic>Cardiovascular Diseases - etiology</topic><topic>Cardiovascular Diseases - mortality</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Evidence-Based Medicine</topic><topic>Female</topic><topic>Hemorrhage - chemically induced</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Primary Prevention - methods</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Research Design</topic><topic>Risk Assessment</topic><topic>Scotland - epidemiology</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Minar, E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>VASA</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Minar, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AAA- a further step towards a moratorium for aspirin in the primary prevention</atitle><jtitle>VASA</jtitle><addtitle>Vasa</addtitle><date>2010-05</date><risdate>2010</risdate><volume>39</volume><issue>2</issue><spage>119</spage><epage>122</epage><pages>119-122</pages><issn>0301-1526</issn><eissn>1664-2872</eissn><cop>Switzerland</cop><pmid>20521434</pmid><doi>10.1024/0301-1526/a000016</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-1526 |
| ispartof | VASA, 2010-05, Vol.39 (2), p.119-122 |
| issn | 0301-1526 1664-2872 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733150135 |
| source | MEDLINE; Hogrefe eContent |
| subjects | Aged Ankle Brachial Index Aspirin - adverse effects Aspirin - therapeutic use Atherosclerosis - complications Atherosclerosis - diagnosis Atherosclerosis - drug therapy Atherosclerosis - mortality Cardiovascular Agents - adverse effects Cardiovascular Agents - therapeutic use Cardiovascular Diseases - etiology Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Evidence-Based Medicine Female Hemorrhage - chemically induced Humans Male Middle Aged Primary Prevention - methods Randomized Controlled Trials as Topic Research Design Risk Assessment Scotland - epidemiology Time Factors Treatment Outcome |
| title | AAA- a further step towards a moratorium for aspirin in the primary prevention |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T09%3A25%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AAA-%20a%20further%20step%20towards%20a%20moratorium%20for%20aspirin%20in%20the%20primary%20prevention&rft.jtitle=VASA&rft.au=Minar,%20E&rft.date=2010-05&rft.volume=39&rft.issue=2&rft.spage=119&rft.epage=122&rft.pages=119-122&rft.issn=0301-1526&rft.eissn=1664-2872&rft_id=info:doi/10.1024/0301-1526/a000016&rft_dat=%3Cproquest_cross%3E733150135%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733150135&rft_id=info:pmid/20521434&rfr_iscdi=true |